BIOCRYST PHARMACEUTICALS, INC. Retained Earnings
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Retained Earnings of -$2.15 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$2.15B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$2.23B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.51B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.75B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$2.15B 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$2.23B 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$1.51B 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$1.75B 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$1.76B 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$1.77B 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$1.77B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.74B 10-Q · filed 2024-11-05 |
| 2024-06-30 | -$1.73B 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$1.72B 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$1.68B 10-K · filed 2025-02-25 |
| 2023-09-30 | -$1.62B 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$1.58B 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$1.51B 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$1.45B 10-K · filed 2024-02-27 |
| 2022-09-30 | -$1.38B 10-Q · filed 2022-11-04 |
| 2022-06-30 | -$1.34B 10-Q · filed 2022-08-05 |
| 2022-03-31 | -$1.28B 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$1.21B 10-K · filed 2023-02-27 |
| 2021-09-30 | -$1.19B 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$1.13B 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$1.09B 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$1.02B 10-K · filed 2022-02-28 |
| 2020-09-30 | -$962.95M 10-Q · filed 2020-11-06 |
| 2020-06-30 | -$916.83M 10-Q · filed 2020-08-07 |
| 2020-03-31 | -$878.23M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$840.63M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$838.01M 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$800.41M 10-Q · filed 2019-08-08 |
| 2019-03-31 | -$762.78M 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$731.97M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$704.54M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$674.94M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$656.49M 10-Q · filed 2018-05-09 |
| 2018-01-01 | -$630.72M 10-K · filed 2019-03-14 |
| 2017-12-31 | -$631.84M 10-K · filed 2019-03-14 |
| 2017-09-30 | -$612.30M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$597.17M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$580.28M 10-Q · filed 2017-05-08 |
| 2016-12-31 | -$566.06M 10-K · filed 2018-03-12 |
| 2016-09-30 | -$561.56M 10-Q · filed 2016-11-08 |
| 2016-06-30 | -$550.03M 10-Q · filed 2016-08-08 |
| 2016-03-31 | -$533.75M 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$510.92M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$492.78M 10-Q · filed 2015-11-06 |
| 2015-06-30 | -$478.16M 10-Q · filed 2015-08-07 |
| 2015-03-31 | -$483.06M 10-Q · filed 2015-05-08 |
| 2014-12-31 | -$467.90M 10-K · filed 2016-02-26 |
| 2014-09-30 | -$456.23M 10-Q · filed 2014-11-07 |
| 2014-06-30 | -$447.50M 10-Q · filed 2014-08-08 |
| 2014-03-31 | -$432.85M 10-Q · filed 2014-05-09 |
| 2013-12-31 | -$422.71M 10-K · filed 2015-03-02 |
| 2013-09-30 | -$417.28M 10-Q · filed 2013-11-08 |
| 2013-06-30 | -$409.28M 10-Q · filed 2013-08-08 |
| 2013-03-31 | -$397.11M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$392.60M 10-K · filed 2014-03-10 |
| 2012-09-30 | -$381.55M 10-Q · filed 2012-11-08 |
| 2012-06-30 | -$371.85M 10-Q · filed 2012-08-08 |
| 2012-03-31 | -$359.57M 10-Q · filed 2012-05-08 |
| 2011-12-31 | -$353.52M 10-K · filed 2013-03-11 |
| 2011-09-30 | -$340.33M 10-Q · filed 2011-11-03 |
| 2011-06-30 | -$325.87M 10-Q · filed 2011-08-04 |
| 2010-12-31 | -$296.57M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |